Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Breast Milk
NCT02154425Phase 1Completed
- Sponsor
- UCB
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of certolizumab pegol in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), Crohn's disease and 2 more, sponsored by UCB. Primary endpoints: The Concentration of Certolizumab Pegol (CZP) in Breast Milk at Day 28, The Calculated Daily Infant Dose of Certolizumab Pegol (CZP) in Breast Milk at Day 28 and 1 more. Started Sep 2014; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)Crohn's diseasepsoriatic arthritis (PsA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02154425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154425.